CytoDyn Inc. (CYDY)
OTCMKTS
· Delayed Price · Currency is USD
0.220
0.00 (0.05%)
Jan 23, 2025, 4:00 PM EST
CytoDyn Statistics
Total Valuation
CytoDyn has a market cap or net worth of 268.61 million. The enterprise value is 276.01 million.
Market Cap | 268.61M |
Enterprise Value | 276.01M |
Important Dates
The last earnings date was Thursday, January 9, 2025.
Earnings Date | Jan 9, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
CytoDyn has 1.23 billion shares outstanding. The number of shares has increased by 19.97% in one year.
Current Share Class | n/a |
Shares Outstanding | 1.23B |
Shares Change (YoY) | +19.97% |
Shares Change (QoQ) | +1.93% |
Owned by Insiders (%) | 0.06% |
Owned by Institutions (%) | 0.02% |
Float | 1.23B |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
PB Ratio | n/a |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -17.55 |
EV / Sales | n/a |
EV / EBITDA | 31.36 |
EV / EBIT | 31.79 |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.35
Current Ratio | 0.35 |
Quick Ratio | 0.33 |
Debt / Equity | n/a |
Debt / EBITDA | 3.27 |
Debt / FCF | n/a |
Interest Coverage | 1.40 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | 31.81% |
Return on Capital (ROIC) | n/a |
Revenue Per Employee | n/a |
Profits Per Employee | -1.75M |
Employee Count | 9 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +19.45% in the last 52 weeks. The beta is -0.11, so CytoDyn's price volatility has been lower than the market average.
Beta (5Y) | -0.11 |
52-Week Price Change | +19.45% |
50-Day Moving Average | 0.13 |
200-Day Moving Average | 0.14 |
Relative Strength Index (RSI) | 80.76 |
Average Volume (20 Days) | 3,038,130 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | 7.38 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | 8.68M |
Pretax Income | -14.25M |
Net Income | -15.73M |
EBITDA | 8.70M |
EBIT | 8.68M |
Earnings Per Share (EPS) | -0.02 |
Balance Sheet
The company has 21.34 million in cash and 28.74 million in debt, giving a net cash position of -7.41 million or -0.01 per share.
Cash & Cash Equivalents | 21.34M |
Total Debt | 28.74M |
Net Cash | -7.41M |
Net Cash Per Share | -0.01 |
Equity (Book Value) | -89.39M |
Book Value Per Share | -0.07 |
Working Capital | -45.99M |
Cash Flow
Operating Cash Flow | -2.13M |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
CytoDyn does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -19.97% |
Shareholder Yield | -19.97% |
Earnings Yield | -5.86% |
FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |